Safety, Tolerance, Pharmacokinetics and Activity of HE3286 in Patients With Rheumatoid Arthritis

Main Inclusion Criteria: * Male or female patient 18-75 years of age * Patient with stable or active disease on a stable dose of methotrexate for at least 30 days prior to Day 1 * Patient has normal thyroid stimulating hormone (TSH) levels with or without thyroid replacement therapy * Patient is willing to abstain from consuming grapefruit containing products from 24 hours prior to dosing until the end of the study as it may affect the pharmacokinetic measurements * Patient has not experienced renal or liver disease by history and/or based on laboratory results * Patient has not experienced acute cardiac disease within 6 months prior to Screening * Patient must provide voluntary, written, informed consent prior to screening evaluations and be able to follow verbal and written instructions. Main Exclusion Criteria: * Functional status class IV according to The American College of Rheumatology (ACR) criteria * Patient who has a history of clinically significant cardiovascular disease (including coronary artery disease), clinically significant hepatic, respiratory or renal abnormalities, or clinically significant endocrine disorders (including diabetes) * Patient with active Tuberculosis (TB) or evidence of latent TB without previous adequate therapy * Systemic autoimmune disorder (including, but not limited to, systemic lupus erythematosus, inflammatory bowel disease, scleroderma, inflammatory myopathy, mixed connective tissue disease or any overlap syndrome) * Inflammatory joint disease other than RA * Patient who has received any of the following immunosuppressive drugs: * Etanercept within 1 month of Day 1; * Abatacept, adalimumab, infliximab, leflunomide, imuran, cyclosporin, anakinra, sulfasalazine, bextra, celebrex or gold within 2 months of Day 1 or for biological agents 6 half lives, whichever is greater; * Rituximab within 1 year of Day 1 * Patient that is bed or wheelchair bound * Patients taking prednisone within 2 weeks prior to Screening * Patient requiring or receiving any of the following within thirty (30) days prior to the screening visit: interleukins, steroids (i.e., anabolic steroids, glucocorticoids), hormone replacement therapy (except stable low-dose HRT for at least 6-months prior to screening), birth control pills, anti-cancer chemotherapeutic agents (except methotrexate), metabolic inhibitors (except methotrexate), concomitant medications that prolong the QT/QTc interval * Patient who has any clinically significant abnormalities in laboratory results at Screening